Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Acta Radiol Retrieve available abstracts of 7 articles: HTML format

Single Articles

July 2022
1. STEVENS WM, Parchment-Smith C, Melling PP, Smith JT, et al
   Making an art into a science: a mathematical "Likert tool" can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer.
   Acta Radiol. 2022 Jul 11:2841851221112194. doi: 10.1177/02841851221112194.
   PubMed     Abstract available
   
   
   June 2022
2. MAKELA P, Wright C, Anttinen M, Bostrom PJ, et al
   Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers.
   Acta Radiol. 2022 Jun 24:2841851221108292. doi: 10.1177/02841851221108292.
   PubMed     Abstract available
   
   
   
3. LEBOVICI A, Csutak C, Popa P, Crisan N, et al
   Magnetic resonance imaging characteristics of chronic prostatitis in patients under the age of 50: is it more than the eye can see?
   Acta Radiol. 2022;63:839-846.
   PubMed     Abstract available
   
   
   April 2022
4. CHUNG JH, Park BK
   Transrectal ultrasound features and biopsy outcomes of transition PI-RADS 5.
   Acta Radiol. 2022;63:559-565.
   PubMed     Abstract available
   
   
   February 2022
5. PARK SB
   Quantitative relaxation maps from synthetic MRI for prostate cancer.
   Acta Radiol. 2022 Feb 24:2841851221077405. doi: 10.1177/02841851221077405.
   PubMed    
   
   
   September 2021
6. THOMSEN HS
   International Scientific Prize.
   Acta Radiol. 2021;62:1131.
   PubMed    
   
   
   June 2021
7. LINHARES MOREIRA AS, De Visschere P, Van Praet C, Villeirs G, et al
   How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.
   Acta Radiol. 2021;62:839-847.
   PubMed     Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: